Physician profile
Mohammad Khan
NPI 1376070540
$1,672.86
in general payments reported to CMS, 2019-2025
32 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $450 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Education: $58.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.49 |
| Education | $58.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $328.67 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $216.15 | 2025 | |
| Genzyme Corporation | $108.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $99.38 | 2024-2025 | Tagrisso, Enhertu |
| Abbvie INC. | $77.24 | 2024-2025 | |
| Stemline Therapeutics INC. | $69.90 | 2024-2025 | Orserdu |
| Geron Corporation | $61.57 | 2025 | Rytelo |
| Lilly USA, LLC | $56.64 | 2024 | Jaypirca, Retevmo, Verzenio |
| Gilead Sciences, INC. | $51.49 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $48.67 | 2024-2025 | Erleada, Carvykti, Balversa |
| Regeneron Healthcare Solutions, INC. | $47.81 | 2024-2025 | Libtayo |
| Array Biopharma INC | $43.00 | 2025 | Braftovi, Mektovi, Tukysa |
| Genentech USA, INC. | $39.73 | 2024-2025 | Polivy, Tecentriq |
| Jazz Pharmaceuticals INC. | $30.14 | 2025 | |
| Syndax Pharmaceuticals, INC. | $29.92 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $29.88 | 2024 | |
| Alexion Pharmaceuticals, INC. | $29.82 | 2025 | Ultomiris |
| Incyte Corporation | $29.45 | 2025 | Jakafi |
| Puma Biotechnology, INC. | $29.41 | 2025 | |
| Agios Pharmaceuticals, INC. | $26.63 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $25.84 | 2025 | Fruzaqla |
| Ardelyx, INC. | $24.32 | 2024 | Ibsrela |
| Kite Pharma, INC. | $22.39 | 2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $20.93 | 2025 | Opdualag |
| Sun Pharmaceutical Industries INC. | $20.69 | 2024 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Secura Bio, INC. | $19.13 | 2024 | Copiktra |
| Amgen INC. | $17.20 | 2024 | Prolia, Evenity |
| Spectrum Pharmaceuticals INC. | $17.19 | 2024 | Rolvedon |
| Glaxosmithkline, LLC. | $17.10 | 2025 | Ojjaara |
| Adc Therapeutics America, INC. | $14.42 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.